. 2016 Sep 19;6:33524. doi: 10.1038/srep33524

Table 2. Proliferation inhibiting effect of different treatments on HepG2 cells.

Group	Proliferation inhibition (%, mean ± s, n = 5)
blank control group	0
Adriamycin group	71.68 ± 2.06^a,c,d,f
nuclide-alone group	43.91 ± 4.58^a,b,d,e,f
MFH-alone group	60.33 ± 3.71^a,b,c,e,f
nuclide-gene group	74.97 ± 1.91^a,c,d,f
nuclide-gene-MFH group	94.51 ± 0.91^a,b,c,d,e

^ap < 0.000 versus blank control group; ^bp < 0.001 versus adriamycin group; ^cp < 0.001 versus nuclide-alone group; ^dp < 0.05 versus MFH-alone group; ^ep < 0.05 versus nuclide-gene group; ^fp < 0.001 versus nuclide-gene-MFH group.